Physician profile
Haris Kamal
NPI 1619213386
$20,621.36
in general payments reported to CMS, 2019-2025
22 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $47.00 · 2021: $1,154 · 2022: $5,086 · 2023: $2,966 · 2024: $10K · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,250 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,250 · Food and Beverage: $2,441 · Travel and Lodging: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,250.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,250.00 |
| Food and Beverage | $2,441.11 |
| Travel and Lodging | $947.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microvention, INC. | $7,135.85 | 2022-2024 | Eric Retrieval Device, Stent, Sofia 6f-131cm Str |
| Philips North America LLC | $5,800.00 | 2022-2024 | (0073) Igt Enabling Functio |
| Scientia Vascular | $4,359.66 | 2023-2024 | Socrates 38 |
| Medtronic, INC. | $841.38 | 2021-2025 | Vantage Anterior Fixation System, Solitaire X, Rist |
| Stryker Corporation | $683.18 | 2019-2025 | Trevo, Augment Injectable, Target |
| Depuy Synthes Sales INC. | $474.22 | 2021-2025 | Embotrap, Emboguard, N/A |
| Astrazeneca Pharmaceuticals Lp | $255.58 | 2021 | |
| Allergan, INC. | $189.29 | 2019 | |
| Phenox INC. | $175.00 | 2021 | |
| Imperative Care, INC | $148.73 | 2022 | |
| Ucb, INC. | $113.67 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $99.76 | 2019 | |
| Amgen INC. | $54.45 | 2019-2025 | Repatha |
| Azurity Pharmaceuticals, INC. | $48.49 | 2024 | Horizant |
| Biogen, INC. | $44.94 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $41.16 | 2025 | Cala Kiq |
| Penumbra, INC. | $40.32 | 2022-2025 | Red 72 |
| Medtronic USA, INC. | $32.33 | 2020 | |
| Abbvie INC. | $23.74 | 2025 | |
| Genentech USA, INC. | $22.31 | 2025 | Ocrevus Zunovo |
| Microtransponder, INC. | $20.48 | 2025 | |
| Acadia Pharmaceuticals INC | $16.82 | 2025 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Kamal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.